David Piontkowsky

613 total citations
27 papers, 458 citations indexed

About

David Piontkowsky is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, David Piontkowsky has authored 27 papers receiving a total of 458 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 17 papers in Virology and 11 papers in Emergency Medicine. Recurrent topics in David Piontkowsky's work include HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (17 papers) and HIV/AIDS Research and Interventions (14 papers). David Piontkowsky is often cited by papers focused on HIV/AIDS drug development and treatment (23 papers), HIV Research and Treatment (17 papers) and HIV/AIDS Research and Interventions (14 papers). David Piontkowsky collaborates with scholars based in United States, United Kingdom and Spain. David Piontkowsky's co-authors include Kirsten White, José Ramón Arribas, Ian R. McNicholl, Giovanni Di Perri, Will Garner, Joseph Gathe, Gilles Pialoux, Ramin Ebrahimi, Pablo Tebas and Jacques Reynes and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

David Piontkowsky

26 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Piontkowsky United States	12	422	269	206	77	34	27	458
Gianmaria Baldin Italy	13	387 0.9×	294 1.1×	124 0.6×	84 1.1×	27 0.8×	50	457
Awny Farajallah United States	8	599 1.4×	408 1.5×	243 1.2×	85 1.1×	19 0.6×	12	649
David Shamblaw United States	6	341 0.8×	239 0.9×	143 0.7×	48 0.6×	24 0.7×	7	379
Arturo Ciccullo Italy	13	430 1.0×	307 1.1×	148 0.7×	126 1.6×	29 0.9×	70	510
Elisabetta Chiesa Italy	11	306 0.7×	242 0.9×	96 0.5×	63 0.8×	14 0.4×	17	351
Ya-Pei Liu United States	10	465 1.1×	347 1.3×	167 0.8×	74 1.0×	28 0.8×	16	518
Marie-Aude Khuong-Josses France	9	530 1.3×	364 1.4×	175 0.8×	120 1.6×	29 0.9×	18	568
Martin Gartland United Kingdom	11	794 1.9×	634 2.4×	262 1.3×	117 1.5×	42 1.2×	19	866
Christiane Moecklinghoff Germany	14	592 1.4×	492 1.8×	258 1.3×	103 1.3×	25 0.7×	34	728
Antonio Antela Spain	8	300 0.7×	214 0.8×	98 0.5×	57 0.7×	12 0.4×	22	353

Countries citing papers authored by David Piontkowsky

Since Specialization

Citations

This map shows the geographic impact of David Piontkowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Piontkowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Piontkowsky more than expected).

Fields of papers citing papers by David Piontkowsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Piontkowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Piontkowsky. The network helps show where David Piontkowsky may publish in the future.

Co-authorship network of co-authors of David Piontkowsky

This figure shows the co-authorship network connecting the top 25 collaborators of David Piontkowsky. A scholar is included among the top collaborators of David Piontkowsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Piontkowsky. David Piontkowsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maggiolo, Franco, Giuliano Rizzardini, Jean‐Michel Molina, et al.. (2022). Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age. HIV Medicine. 24(1). 27–36. 27 indexed citations

Rizzardini, Giuliano, Jean‐Michel Molina, Federico Pulido, et al.. (2021). Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial. Infectious Diseases and Therapy. 10(2). 775–788. 40 indexed citations

Huhn, Gregory, Moti Ramgopal, Mamta K. Jain, et al.. (2020). HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS ONE. 15(1). e0224875–e0224875. 5 indexed citations

Valero, Ignacio, Josep M. Llibre, Antonella Castagna, et al.. (2020). Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation. JAIDS Journal of Acquired Immune Deficiency Syndromes. 86(4). 490–495. 5 indexed citations

Ys, Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.. (2019). Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. SHILAP Revista de lepidopterología. 20(3). 73–81. 9 indexed citations

Rizzardini, Giuliano, François Raffi, Federico Pulido, et al.. (2019). Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial. The Lancet HIV. 6(10). e655–e666. 32 indexed citations

Rizzardini, Giuliano, Andrea Gori, Celia Miralles, et al.. (2019). Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. AIDS. 33(10). 1583–1593. 6 indexed citations

White, Kirsten, Will Garner, Joseph J. Eron, et al.. (2018). Repeat testing of low-level HIV-1 RNA. AIDS. 32(8). 1053–1057. 1 indexed citations

Llibre, Josep M., François Raffi, Graeme Moyle, et al.. (2016). An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PLoS ONE. 11(5). e0155406–e0155406. 4 indexed citations

10.

Lunzen, Jan van, Andrea Antinori, Calvin Cohen, et al.. (2015). Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults. AIDS. 30(2). 251–259. 27 indexed citations

11.

Arribas, José Ramón, Gilles Pialoux, Joseph Gathe, et al.. (2014). Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. The Lancet Infectious Diseases. 14(7). 581–589. 89 indexed citations

12.

Gazzard, Brian, Pierre Marie Girard, Giovanni Di Perri, et al.. (2014). Long‐term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV‐1‐infected treatment‐naïve subjects ≥50 years. Journal of the International AIDS Society. 17(4S3). 19767–19767. 2 indexed citations

13.

Pozniak, Anton, Martin Markowitz, Anthony Mills, et al.. (2014). Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial. The Lancet Infectious Diseases. 14(7). 590–599. 75 indexed citations

14.

Winston, Jonathan, Michel Chonchol, Joel E. Gallant, et al.. (2014). Discontinuation of Tenofovir Disoproxil Fumarate for Presumed Renal Adverse Events in Treatment-Naïve HIV-1 Patients: Meta-analysis of Randomized Clinical Studies. HIV Clinical Trials. 15(6). 231–245. 21 indexed citations

15.

Stellbrink, Hans‐Juergen, Andrea Antinori, Anton Pozniak, et al.. (2014). Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐NNRTI subgroup analysis. Journal of the International AIDS Society. 17(4S3). 19793–19793. 6 indexed citations

16.

Bouée, S., et al.. (2014). An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine. Journal of the International AIDS Society. 17(4S3). 19779–19779. 1 indexed citations

17.

Post, Frank, Jonathan Winston, Brian Gazzard, et al.. (2013). Week 96 renal safety update of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from two phase 3 randomized controlled trials. Journal of the International AIDS Society. 16(Suppl 1). 1 indexed citations

18.

Campo, Rafael, E DeJesus, U. Fritz Bredeek, et al.. (2013). SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen. Clinical Infectious Diseases. 56(11). 1637–1645. 36 indexed citations

19.

Venkat, Arvind, et al.. (2008). Care of the HIV-Positive Patient in the Emergency Department in the Era of Highly Active Antiretroviral Therapy. Annals of Emergency Medicine. 52(3). 274–285. 15 indexed citations

20.

Venkat, Arvind, et al.. (2008). Emergency department utilization by HIV-positive adults in the HAART era. International Journal of Emergency Medicine. 1(4). 287–296. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact